A Multicenter, Randomized, Double-blind, Vehicle-Controlled, Phase 2 Study of TER-101 Topical Ointment to Assess Efficacy and Safety in Subjects With Mild to Moderate Atopic Dermatitis
Latest Information Update: 21 Jul 2022
At a glance
- Drugs TER-101 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Teres Bio
- 04 May 2021 Status changed from active, no longer recruiting to completed.
- 19 Mar 2021 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2021 New trial record